243 related articles for article (PubMed ID: 34085829)
21. Intracellular signaling pathways regulate hormone-dependent kallikrein gene expression.
Paliouras M; Diamandis EP
Tumour Biol; 2008; 29(2):63-75. PubMed ID: 18515984
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of kallikrein-related peptidase transcript levels in prostate cancer.
Lehto TK; Kovanen RM; Lintula S; Malén A; Stürenberg C; Erickson A; Pulkka OP; Stenman UH; Diamandis EP; Rannikko A; Mirtti T; Koistinen H
Int J Cancer; 2023 Aug; 153(4):867-881. PubMed ID: 37139608
[TBL] [Abstract][Full Text] [Related]
23. Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.
Yoon H; Blaber SI; Evans DM; Trim J; Juliano MA; Scarisbrick IA; Blaber M
Protein Sci; 2008 Nov; 17(11):1998-2007. PubMed ID: 18697857
[TBL] [Abstract][Full Text] [Related]
24. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
Scorilas A; Mavridis K
Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
[TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis and Biological Evaluation of 1-methyl-1H-pyrazole-5-Carboxamide Derivatives as Novel Anti-Prostate Cancer Agents.
Chen X; Xu C; Li Y; Duan X; Zhao G
Anticancer Agents Med Chem; 2021; 21(17):2368-2378. PubMed ID: 33530916
[TBL] [Abstract][Full Text] [Related]
26. Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.
de Veer SJ; Furio L; Swedberg JE; Munro CA; Brattsand M; Clements JA; Hovnanian A; Harris JM
J Invest Dermatol; 2017 Feb; 137(2):430-439. PubMed ID: 27697464
[TBL] [Abstract][Full Text] [Related]
27. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
[TBL] [Abstract][Full Text] [Related]
28. The kallikrein-related peptidase family: Dysregulation and functions during cancer progression.
Kryza T; Silva ML; Loessner D; Heuzé-Vourc'h N; Clements JA
Biochimie; 2016 Mar; 122():283-99. PubMed ID: 26343558
[TBL] [Abstract][Full Text] [Related]
29. Kallikrein gene family as biomarkers for recurrent prostate cancer.
Boyukozer FB; Tanoglu EG; Ozen M; Ittmann M; Aslan ES
Croat Med J; 2020 Oct; 61(5):450-456. PubMed ID: 33150763
[TBL] [Abstract][Full Text] [Related]
30. Proteomic and other analyses to determine the functional consequences of deregulated kallikrein-related peptidase (KLK) expression in prostate and ovarian cancer.
Fuhrman-Luck RA; Silva ML; Dong Y; Irving-Rodgers H; Stoll T; Hastie ML; Loessner D; Gorman JJ; Clements JA
Proteomics Clin Appl; 2014 Jun; 8(5-6):403-15. PubMed ID: 24535680
[TBL] [Abstract][Full Text] [Related]
31. Kallikrein-related peptidase 14 is the second KLK protease targeted by the serpin vaspin.
Ulbricht D; Tindall CA; Oertwig K; Hanke S; Sträter N; Heiker JT
Biol Chem; 2018 Sep; 399(9):1079-1084. PubMed ID: 29494334
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.
Williams SA; Xu Y; De Marzo AM; Isaacs JT; Denmeade SR
Prostate; 2010 May; 70(7):788-96. PubMed ID: 20058238
[TBL] [Abstract][Full Text] [Related]
33. A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus.
Kaushal A; Myers SA; Dong Y; Lai J; Tan OL; Bui LT; Hunt ML; Digby MR; Samaratunga H; Gardiner RA; Clements JA; Hooper JD
Prostate; 2008 Mar; 68(4):381-99. PubMed ID: 18196551
[TBL] [Abstract][Full Text] [Related]
34. Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines.
Shaw JL; Diamandis EP
Biol Chem; 2008 Nov; 389(11):1409-19. PubMed ID: 19031603
[TBL] [Abstract][Full Text] [Related]
35. Kallikreins as microRNA targets: an in silico and experimental-based analysis.
Chow TF; Crow M; Earle T; El-Said H; Diamandis EP; Yousef GM
Biol Chem; 2008 Jun; 389(6):731-8. PubMed ID: 18627289
[TBL] [Abstract][Full Text] [Related]
36. Distribution of 15 human kallikreins in tissues and biological fluids.
Shaw JL; Diamandis EP
Clin Chem; 2007 Aug; 53(8):1423-32. PubMed ID: 17573418
[TBL] [Abstract][Full Text] [Related]
37. Inhibitors of kallikrein-related peptidases: An overview.
Masurier N; Arama DP; El Amri C; Lisowski V
Med Res Rev; 2018 Mar; 38(2):655-683. PubMed ID: 28609548
[TBL] [Abstract][Full Text] [Related]
38. The GNA13-RhoA signaling axis suppresses expression of tumor protective Kallikreins.
Teo CR; Casey PJ; Rasheed SA
Cell Signal; 2016 Oct; 28(10):1479-88. PubMed ID: 27424208
[TBL] [Abstract][Full Text] [Related]
39. Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.
Liu X; Chen X; Rycaj K; Chao HP; Deng Q; Jeter C; Liu C; Honorio S; Li H; Davis T; Suraneni M; Laffin B; Qin J; Li Q; Yang T; Whitney P; Shen J; Huang J; Tang DG
Oncotarget; 2015 Sep; 6(27):23959-86. PubMed ID: 26246472
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there.
Pasic MD; Olkhov E; Bapat B; Yousef GM
Biol Chem; 2012 Apr; 393(5):319-30. PubMed ID: 22505515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
